Sustained Monomorphic Ventricular Tachycardia During Imatinib Therapy in Blast-Phase Chronic Myeloid Leukemia: A Case Report from a Resource-Limited Setting

Background: Imatinib has substantially improved the treatment of chronic myeloid leukemia (CML) and is generally associated with a favorable cardiovascular safety profile. Nevertheless, serious arrhythmias occurring during treatment may present a diagnostic challenge, particularly in patients with advanced disease and multiple potential contributing factors. Case presentation: A 45-year-old woman with CML in blast phase developed sustained monomorphic ventricular tachycardia (VT) during treatment with imatinib. Bone marrow examination showed 66% blasts, and her clinical course was complicated by severe anemia and metabolic abnormalities. During the arrhythmic episode, her heart rate was approximately 198 beats/min and blood pressure was 93/61 mmHg. She remained conscious, with palpable pulses and preserved peripheral perfusion. The ventricular tachycardia persisted despite two intravenous amiodarone loading doses and subsequently converted to sinus rhythm following synchronized electrical cardioversion. No recurrence was documented during the subsequent observation period. The event occurred in the setting of advanced malignancy and other potential clinical contributors, making its cause difficult to determine. Conclusion: This case illustrates the challenge of evaluating ventricular tachycardia in a patient with advanced CML receiving imatinib. A treatment-related arrhythmia is a possibility, but the clinical context includes several competing contributors and does not establish a definitive cause. Assessment of serious arrhythmias during cancer treatment should consider medication exposure, the underlying disease, and potentially reversible clinical factors.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-19
DOI
https://doi.org/10.21203/rs.3.rs-11605710/v1
Primary Topic
Chronic Myeloid Leukemia Treatments
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Sustained Monomorphic Ventricular Tachycardia During Imatinib Therapy in Blast-Phase Chronic Myeloid Leukemia: A Case Report from a Resource-Limited Setting

Selamawit Kassahun Aweke, Leul Tesfaye Kidane, Yohana Bezabih Kelile, Abdulhakim Muste Awol et al.
Research Square
Chronic Myeloid Leukemia Treatments
preprint

Sustained Monomorphic Ventricular Tachycardia During Imatinib Therapy in Blast-Phase Chronic Myeloid Leukemia: A Case Report from a Resource-Limited Setting

Selamawit Kassahun Aweke, Leul Tesfaye Kidane, Yohana Bezabih Kelile, Abdulhakim Muste Awol, Natnael Mathewos Assele, Ruth Lesan Lakew, Ayenew Amare Wole
preprint en

Abstract

Background: Imatinib has substantially improved the treatment of chronic myeloid leukemia (CML) and is generally associated with a favorable cardiovascular safety profile. Nevertheless, serious arrhythmias occurring during treatment may present a diagnostic challenge, particularly in patients with advanced disease and multiple potential contributing factors. Case presentation: A 45-year-old woman with CML in blast phase developed sustained monomorphic ventricular tachycardia (VT) during treatment with imatinib. Bone marrow examination showed 66% blasts, and her clinical course was complicated by severe anemia and metabolic abnormalities. During the arrhythmic episode, her heart rate was approximately 198 beats/min and blood pressure was 93/61 mmHg. She remained conscious, with palpable pulses and preserved peripheral perfusion. The ventricular tachycardia persisted despite two intravenous amiodarone loading doses and subsequently converted to sinus rhythm following synchronized electrical cardioversion. No recurrence was documented during the subsequent observation period. The event occurred in the setting of advanced malignancy and other potential clinical contributors, making its cause difficult to determine. Conclusion: This case illustrates the challenge of evaluating ventricular tachycardia in a patient with advanced CML receiving imatinib. A treatment-related arrhythmia is a possibility, but the clinical context includes several competing contributors and does not establish a definitive cause. Assessment of serious arrhythmias during cancer treatment should consider medication exposure, the underlying disease, and potentially reversible clinical factors.

Research Square
Addis Ababa University (ET)
Chronic Myeloid Leukemia Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon